Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy

International Journal of Pharmaceutics

Volumn 450, Issue 1-2, 2013, Pages 278-289

  Talekar, Meghna ^a   Ganta, Srinivas ^b   Amiji, Mansoor ^c   Jamieson, Stephen ^d   Kendall, Jackie ^d   Denny, William A ^d   Garg, Sanjay ^a,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Nemucore Medical Innovations Inc   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Folate; Nanosuspension; Phosphatidylinositol 3 kinase; PIK 75; SKOV 3

Indexed keywords

CASPASE 3; CASPASE 7; FOLIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SN 32776; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PURITY; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; ENTRAPMENT EFFICIENCY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MORPHOLOGY; NANOSUSPENSION FORMULATION; NONHUMAN; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SUSPENSION; WESTERN BLOTTING; X RAY POWDER DIFFRACTION; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; FEMALE; FOLIC ACID; FOLIC ACID TRANSPORTERS; HUMANS; HYDRAZONES; MICE; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; POLOXAMER; REACTIVE OXYGEN SPECIES; SOLUBILITY; SULFONAMIDES; SUSPENSIONS;

EID: 84877860261     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.057     Document Type: Article

References (44)

1. B. Asadishad, M. Vossoughi, and I. Alemzadeh Folate-receptor-targeted delivery of doxorubicin using polyethylene glycol-functionalized gold nanoparticles Ind. Eng. Chem. Res. 49 2010 1958 1963
2. A.G. Bader, S. Kang, and P.K. Vogt Cancer-specific mutations in PIK3CA are oncogenic in vivo Proc. Natl. Acad. Sci. U.S.A. 103 2006 1475 1479
3. C. Chaussade, G.W. Rewcastle, J.D. Kendall, W.A. Denny, K. Cho, L.M. Grønning, M.L. Chong, S.H. Anagnostou, S.P. Jackson, N. Daniele, and P.R. Shepherd Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling Biochem. J. 404 2007 449 458
4. ClinicalTrials.gov, 2012a. A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
5. ClinicalTrials.gov, 2012b. Dose Escalation Study of INK1117 in Subjects With Advanced Cancer. U.S. National Institutes of Health.
6. ClinicalTrials.gov, 2012c. A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene. U.S. National Institute of Health.
7. F.F. Feng, D.R. Zhang, K.L. Tian, H.Y. Lou, X.L. Qi, Y.C. Wang, C.X. Duan, L.J. Jia, F.H. Wang, Y. Liu, and Q. Zhang Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension Drug Deliv. 18 2011 265 271
8. R. Frédérick, C. Mawson, J.D. Kendall, C. Chaussade, G.W. Rewcastle, P.R. Shepherd, and W.A. Denny Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening Bioorg. Med. Chem. Lett. 19 2009 5842 5847
9. M. Gymnopoulos, M.A. Elsliger, and P.K. Vogt Rare cancer-specific mutations in PIK3CA show gain of function Proc. Natl. Acad. Sci. U.S.A. 104 2007 5569 5574
10. M. Hayakawa, K.I. Kawaguchi, H. Kaizawa, T. Koizumi, T. Ohishi, M. Yamano, M. Okada, M. Ohta, S.I. Tsukamoto, F.I. Raynaud, P. Parker, P. Workman, and M.D. Waterfield Synthesis and biological evaluation of sulfonylhydrazone- substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors Bioorg. Med. Chem. 15 2007 5837 5844
11. S. Jamieson, J.U. Flanagan, S. Kolekar, C. Buchanan, J.D. Kendall, W.J. Lee, G.W. Rewcastle, W.A. Denny, R. Singh, J. Dickson, B.C. Baguley, and P.R. Shepherd A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types Biochem. J. 438 2011 53 62
12. C. Kang, X. Yuan, Y. Zhong, P. Pu, Y. Guo, A. Albadany, S. Yu, Z. Zhang, Y. Li, J. Chang, and J. Sheng Evaluation of folate-PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo J. Biomed. Mater. Res. A 93 2010 585 594
13. O. Kayser nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages Int. J. Pharm. 196 2000 253 256
14. J.D. Kendall, G.W. Rewcastle, R. Frederick, C. Mawson, W.A. Denny, E.S. Marshall, B.C. Baguley, C. Chaussade, S.P. Jackson, and P.R. Shepherd Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110[alpha] inhibitors Bioorg. Med. Chem. 15 2007 7677 7687
15. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing - oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644
16. S. Kim, and J. Lee Folate-targeted drug-delivery systems prepared by nano-comminution Drug Dev. Ind. Pharm. 37 2011 131 138
17. Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, T. Balla, W.A. Weiss, R.L. Williams, and K.M. Shokat A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling Cell 125 2006 733 747
18. S. Kohno, M.A. Hossain, S. Maesaki, E. Sasaki, H. Kakeya, K. Tomono, and Y. Tashiro The efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B against Cryptococcus neoformans Clin. Infect. Dis. 25 1997 489
19. P. Lakshmi, and G.A. Kumar Nanosuspension technology: a review Int. J. Pharm. Pharm. Sci. 2 2010 35 40
20. C.P. Leamon, and P.S. Low Selective targeting of malignant cells with cytotoxin-folate conjugates J. Drug Target. 2 1994 101 112
21. J.J. Lin, J.S. Chen, S.J. Huang, J.H. Ko, Y.M. Wang, T.L. Chen, and L.F. Wang Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications Biomaterials 30 2009 5114 5124
22. F. Liu, J.Y. Park, Y. Zhang, C. Conwell, Y. Liu, S.R. Bathula, and L. Huang Targeted cancer therapy with novel high drug-loading nanocrystals J. Pharm. Sci. 99 2010 3542 3551
23. P. Liu, X. Rong, J. Laru, B. Van Veen, J. Kiesvaara, J. Hirvonen, T. Laaksonen, and L. Peltonen Nanosuspensions of poorly soluble drugs: preparation and development by wet milling Int. J. Pharm. 411 2011 215 222
24. Y. Liu, J. Sun, W. Cao, J. Yang, H. Lian, X. Li, Y. Sun, Y. Wang, S. Wang, and Z. He Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery Int. J. Pharm. 421 2011 160 169
25. H. Lou, L. Gao, X. Wei, Z. Zhang, D. Zheng, D. Zhang, X. Zhang, Y. Li, and Q. Zhang Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice Colloids Surf. B: Biointerfaces 87 2011 319 325
26. H. Lou, X. Zhang, L. Gao, F. Feng, J. Wang, X. Wei, Z. Yu, D. Zhang, and Q. Zhang In vitro and in vivo antitumor activity of oridonin nanosuspension Int. J. Pharm. 379 2009 181 186
27. E. Merisko-Liversidge, P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, J. Rake, J.M. Shaw, S. Pugh, L. Polin, J. Jones, T. Corbett, E. Cooper, and G.G. Liversidge Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Pharm. Res. 13 1996 272 278
28. K.M. Nicholson, and N.G. Anderson The protein kinase B/Akt signalling pathway in human malignancy Cell. Signal. 14 2002 381 395
29. N. Schöler, K. Krause, O. Kayser, R.H. Müller, K. Borner, H. Hahn, and O. Liesenfeld Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis Antimicrob. Agents Chemother. 45 2001 1771 1779
30. L. Shayesteh, Y. Lu, W.L. Kuo, R. Baldocchi, T. Godfrey, C. Collins, D. Pinkel, B. Powell, G.B. Mills, and J.W. Gray PlK3CA is implicated as an oncogene in ovarian cancer Nat. Genet. 21 1999 99 102
31. S.N. Shrikhande, C.A. Chande, V.R. Shegokar, and R.M. Powar Pulmonary cryptosporidiosis in HIV negative, immunocompromised host Indian J. Pathol. Microbiol. 52 2009 267 268
32. G. Song, G. Ouyang, and S. Bao The activation of Akt/PKB signaling pathway and cell survival J. Cell. Mol. Med. 9 2005 59 71
33. M. Talekar, S. Ganta, A. Singh, M. Amiji, J. Kendall, W.A. Denny, and S. Garg Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells Pharm. Res. 2012 1 13
34. M. Talekar, J. Kendall, W. Denny, and S. Garg Targeting of nanoparticles in cancer: drug delivery and diagnostics Anticancer Drugs 22 2011 949 962
35. M. Talekar, J. Kendall, W. Denny, S. Jamieson, and S. Garg Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol-3-kinase inhibitor Eur. J. Pharm. Sci. 47 2012 824 833
36. H.A.C. Titulaer, W.M.C. Eling, D.J.A. Crommelin, P.A.M. Peeters, and J. Zuidema The parenteral controlled release of liposome encapsulated chloroquine in mice J. Pharm. Pharmacol. 42 1990 529 532
37. M. Tsai, Z. Lu, J. Wang, T.K. Yeh, M.G. Wientjes, and J.L.S. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 2007 1691 1701
38. I.F. Uchegbu, J.A. Turton, J.A. Double, and A.T. Florence Drug distribution and a pulmonary adverse effect of intraperitoneally administered doxorubicin niosomes in the mouse Biopharm. Drug Dispos. 15 1994 691 707
39. C. Wang, and A.J. Hickey Isoxyl particles for pulmonary delivery: in vitro cytotoxicity and potency Int. J. Pharm. 396 2010 99 104
40. M.E. Werner, S. Karve, R. Sukumar, N.D. Cummings, J.A. Copp, R.C. Chen, T. Zhang, and A.Z. Wang Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis Biomaterials 32 2011 8548 8554
41. K.A. West, S. Sianna Castillo, and A. Dennis Phillip Activation of the PI3K/Akt pathway and chemotherapeutic resistance Drug Resist. Updat. 5 2002 234 248
42. X.G. Wu, M. Xin, L.N. Yang, and W.Y. Shi The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits J. Pharm. Sci. 100 2011 1350 1361
43. Y. Zhang, M. Huo, J. Zhou, and S. Xie PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel Comput. Methods Programs Biomed. 99 2010 306 314
44. D. Zheng, Y. Wang, D. Zhang, Z. Liu, C. Duan, L. Jia, F. Wang, Y. Liu, G. Liu, L. Hao, and Q. Zhang In vitro antitumor activity of silybin nanosuspension in PC-3 cells Cancer Lett. 307 2011 158 164